Login to Your Account



Nektar Keeps Promotion Rights In $175M Deal On Amikacin Drug

By Jim Shrine


Tuesday, August 7, 2007
Nektar Therapeutics Inc. is getting $50 million up front and retaining co-promotion rights in a deal with Bayer HealthCare AG covering its Phase II inhaled amikacin product for pneumonia. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription